Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Ohashi, Toshio ^a,b   Yorozu, Atsunori ^c   Saito, Shiro ^c   Momma, Tetsuo ^b   Nishiyama, Toru ^c   Yamashita, Shoji ^b   Shiraishi, Yutaka ^a   Shigematsu, Naoyuki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA NATIONAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Androgen deprivation therapy; Brachytherapy; High risk; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84892164261     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-13     Document Type: Article

References (34)

1. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527. 10.1056/NEJMoa0810095, 19516032.
2. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073. 10.1016/S1470-2045(10)70223-0, 20933466.
3. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063. 10.1016/j.ijrobp.2010.03.049, 21147514.
4. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054, 17765406.
5. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239. 10.1001/jama.294.10.1233, 16160131.
6. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996. 10.1200/JCO.2005.05.2530, 16648499.
7. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 2013, 119:3265-3271. 10.1002/cncr.28213, 23798338.
8. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:1352-1359. 10.1016/j.ijrobp.2004.01.023, 15275720.
9. Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009, 104:1631-1636. 10.1111/j.1464-410X.2009.08661.x, 19493260.
10. Carpenter TJ, Forsythe K, Kao J, Stone NN, Stock RG. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011, 10:261-268. 10.1016/j.brachy.2010.10.002, 21106445.
11. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:341-346. 10.1016/j.ijrobp.2008.04.038, 18597953.
12. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342. 10.1016/j.ijrobp.2010.01.005, 20605342.
13. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504. 10.1200/JCO.2007.14.9021, 18413638.
14. Ohashi T, Yorozu A, Toya K, Saito S, Momma T. Acute urinary morbidity following I-125 prostate brachytherapy. Int J Clin Oncol 2005, 10:262-268. 10.1007/s10147-005-0507-8, 16136372.
15. Ohashi T, Yorozu A, Toya K, Saito S, Momma T, Nagata H, Kosugi M, Shigematsu N, Kubo A. Comparison of intraoperative ultrasound with postimplant computed tomography-dosimetric values at Day 1 and Day 30 after prostate brachytherapy. Brachytherapy 2007, 6:246-253. 10.1016/j.brachy.2007.08.006, 17959425.
16. Yoshida K, Ohashi T, Yorozu A, Toya K, Nishiyama T, Saito S, Hanada T, Shiraishi Y, Shigematsu N. Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy. Jpn J Clin Oncol 2013, 43:383-389. 10.1093/jjco/hys240, 23315386.
17. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533. 10.1016/j.ijrobp.2005.07.981, 16242258.
18. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001, 57:1121-1126. discussion 1126-1127, 10.1016/S0090-4295(01)01051-2, 11377322.
19. Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, Gustafson G, Krauss D, Vicini F, Kestin L. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370. 10.1016/j.ijrobp.2009.10.035, 21195875.
20. Kamrava M, Rwigema JC, Chung M, Banerjee R, Wang J, Steinberg M, Demanes DJ. Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancer. Journal of contemporary brachytherapy 2013, 5:127-133. 3797412, 24143146.
21. D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001, 49:679-684. 10.1016/S0360-3016(00)01423-1, 11172949.
22. Huang J, Vicini FA, Williams SG, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez AA, Kestin LL. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?. Int J Radiat Oncol Biol Phys 2012, 83:1141-1148. 10.1016/j.ijrobp.2011.09.043, 22099043.
23. Wong WW, Schild SE, Vora SA, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:24-29. 10.1016/j.ijrobp.2004.02.031, 15337536.
24. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002, 168:1994-1999. 10.1016/S0022-5347(05)64280-2, 12394693.
25. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 2004, 10:54-60. 10.1097/00130404-200401000-00011, 15000496.
26. Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology 2006, 67:349-353. 10.1016/j.urology.2005.08.047, 16461084.
27. Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys 2012, 82:e773-e779. 10.1016/j.ijrobp.2011.11.023, 22300573.
28. Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Wallner KE. Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy. BJU Int 2010, 106:809-814. 10.1111/j.1464-410X.2010.09269.x, 20201830.
29. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009, 73:659-664. 10.1016/j.ijrobp.2008.05.009, 18692327.
30. D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 2007, 110:56-61. 10.1002/cncr.22737, 17530618.
31. Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ, Scardino PT, Eastham JA. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008, 53:950-959. 10.1016/j.eururo.2007.10.008, 2637146, 17950521.
32. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 2007, 68:34-40. 10.1016/j.ijrobp.2006.11.046, 17289288.
33. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:444-452. 10.1016/S0360-3016(01)02598-6, 11872291.
34. Konaka H, Egawa S, Saito S, Yorozu A, Takahashi H, Miyakoda K, Fukushima M, Dokiya T, Yamanaka H, Stone NN, Namiki M. Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2012, 12:110. 10.1186/1471-2407-12-110, 3350387, 22439742.